Investors

Press Releases

Press Releases

Date Title View
Toggle Summary Liquidia Closes Acquisition of RareGen
Merger   Reinforc es Company’s Commitment to Patients with PAH Paul Manning and Roger Jeffs Join Liquidia Corporation Board of Directors RESEARCH TRIANGLE PARK, N.C. , Nov. 18, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company
View HTML
Toggle Summary Liquidia Announces Results of Special Meeting of Stockholders
Stockholders Approve RareGen Acquisition Merger Expected to Close on   or A bout November 18 , 2020 RESEARCH TRIANGLE PARK, N.C. , Nov. 16, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and
View HTML
Toggle Summary Liquidia to Present at the 2020 Jefferies Virtual London Healthcare Conference
RESEARCH TRIANGLE PARK, N.C. , Nov. 12, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies , Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that Neal
View HTML
Toggle Summary Liquidia Reports Third Quarter 2020 Financial Results and Provides Corporate Update
- Raised $75   M illion through Underwritten Public Offering - Bolstered   and Defended LIQ861 Patent Position - Advanced Efforts in Support of the RareGen, LLC Merger and Integration - Company to Host Webcast and Conference Call Today at 8:00   a.m. ET RESEARCH TRIANGLE PARK, N.C. , Nov.
View HTML
Toggle Summary Liquidia Reschedules Special Meeting of Stockholders and Reaffirms Recommendation to Approve Proposed Acquisition of RareGen, LLC
Company Determines Unsolicited Offer does not Constitute Superior Proposal RESEARCH TRIANGLE PARK, N.C , Nov. 02, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products
View HTML
Toggle Summary Liquidia to Report Third Quarter 2020 Financial Results and Provide Corporate Update on November 6, 2020
Company to Host Webcast and Conference Call November 9, 2020 at 8:00a.m. ET RESEARCH TRIANGLE PARK, N.C. , Oct. 30, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products
View HTML
Toggle Summary Liquidia Announces Postponement of Special Meeting of Stockholders
RESEARCH TRIANGLE PARK, N.C. , Oct. 19, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT ®  technology, today announced that it has
View HTML
Toggle Summary Liquidia Provides Update on U.S. Patent Trial and Appeal Board Decision on Inter Partes Review of Two United Therapeutics’ Tyvaso® Patents
PTAB Institutes Inter Partes Review Proceeding Against United Therapeutics’ ‘901 Patent and Denies Institution on ‘066 Patent for Tyvaso® RESEARCH TRIANGLE PARK, N.C. , Oct. 14, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company
View HTML
Toggle Summary Liquidia Names Gerald M. O’Brien, MD, as Vice President, Pulmonary Clinical Development
Dr. O’Brien Joins Liquidia with 25 Years of Medical Practice Experience in Pulmonary Critical Care RESEARCH TRIANGLE PARK, N.C. , Oct. 05, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and
View HTML
Toggle Summary Liquidia Announces Special Meeting Date to Approve Proposed Acquisition of RareGen, LLC
Special Meeting of Liquidia Technologies, Inc. Stockholders Scheduled for October 21, 2020 RESEARCH TRIANGLE PARK, N.C. , Sept. 17, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization
View HTML